
Patritumab Deruxtecan BLA Withdrawn in Non-Small Cell Lung Cancer
The biologics license application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd) for adult patients with previously treated, locally advanced/metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in the U.S. has been …